Pharmacokinetic-based culture system with biological barriers

• US 20070037277A1
• Filed: 05/17/2006
• Published: 02/15/2007
• Est. Priority Date: 04/25/2001
• Status: Abandoned Application

• Current Assignee: Cornell Research Foundation Incorporated (Cornell University)
• Original Assignee: Cornell Research Foundation Incorporated (Cornell University)
• Inventors: Shuler, Michael, Harrison, Andrew, Meyers, Scott, Sin, Aaron, Baxter, Gregory, Freedruan, Robert
• Application Number:
  US11/436,100
• Publication Number:
  US 20070037277A1
• Time in Patent Office: Days
• US Class Current: 435/297.400
• CPC Class Codes: B01L 3/5027 by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip B01L3/5023 takes precedence; micromixers B01F33/30; microreactors for synthesis B01J19/0093; microcapillary devices in general B81B1/00
• CPC Class Codes: C12M 21/08 for producing artificial tissue or for ex-vivo cultivation of tissue prostheses A61F2/00, grafts A61L27/00
• CPC Class Codes: C12M 23/16 Microfluidic devices; Capillary tubes integrated microfluidic structures B01L3/5027; microreactors B01J19/0093
• CPC Class Codes: C12M 23/34 Internal compartments or partitions
• CPC Class Codes: C12M 23/44 Multiple separable units; Modules
• CPC Class Codes: C12M 29/04 Filters; Permeable or porous membranes or plates, e.g. dialysis

Abstract

Systems and methods are disclosed for microscale pharmacokinetics. Various organs and their interactions with drug compounds can be simulated in vitro by use of microscale compartments that can be interconnected by microscale channels. Cells or cellular materials associated with the organs can be cultured in such compartments to allow interactions with drug compounds in one or more fluidic flows. Such fluidic systems can include, by way of examples, gastrointestinal flow, blood flow, bile flow, urinary flow, and brain fluid flow. Interactions between fluidic systems can be simulated by a microscale permeable member. In one example, blood-biliary interaction can be simulated by a microscale permeable material having hepatocytes bound to a permeable substrate via a binder.

Claims

1. A device comprising:

at least one microscale feature dimensioned to maintain biological material under conditions that provide a value of at least one pharmacokinetic parameter in vitro that is comparable to the value of at least one pharmacokinetic parameter found in vivo; and

a permeable material.

2. The device of claim 1 wherein the permeable material is selected from at least one of the group consisting of a membrane, a porous membrane, microporous silicon, a semi-permeable membrane, a microporous material, a microporous polymer, alginate, collagen, MATRIGEL, cells, cellular material, tissue, and pieces of tissue.

3. The device of claim 1 wherein the permeable material further comprises organic or inorganic material in, on or near a microporous surface.

4. The device of claim 1 wherein the permeable material is configured to simulate at least one of a biological barrier, passage of substances in or through a biological barrier, or absorption of substances in, through or by a biological barrier.

5. The device of claim 4 wherein the biological barrier is selected from at least one of the group consisting of a gastrointestinal barrier, a blood-brain barrier, a pulmonary barrier, a placental barrier, an epidermal barrier, ocular barrier, olfactory barrier, a gastroesophageal barrier, a mucous membrane, a blood-urinary barrier, air-tissue barrier, a blood-biliary barrier, oral barrier, anal rectal barrier, vaginal barrier, and urethral barrier.

6. The device of claim 1 wherein the at least one pharmacokinetic parameter is selected from at least one of the group consisting of tissue size, tissue size ratio, tissue to blood volume ratio, drug residence time, interactions between cells, liquid residence time, liquid to cell ratios, metabolism by cells, shear stress, flow rate, geometry, circulatory transit time, liquid distribution, interactions between tissues and/or organs, and molecular transport by cells.

7. The device of claim 1 wherein the device determines absorption, metabolism, excretion, or distribution of a substance in, through or by the permeable material.

8. The device of claim 1 wherein the feature is configured to represent at least one of the group consisting of at least portions of central nervous, circulatory, digestive, biliary, pulmonary, urinary, ocular, olfactory, epidermal, and lymphatic systems.

9. The device of claim 1 wherein the permeable material is located in or external to the device.

10. The device of claim 1 further comprising at least one microfluidic channel connected to the permeable material.

11. The device of claim 1 wherein the flow of fluid in, through, or in proximity to the permeable material provides the at least one pharmacokinetic parameter.

12. The device of claim 11 wherein the characteristics of the fluid flow through the device are based on a mathematical model.

13. The device of claim 12 wherein the mathematical model is a physiologically-based pharmacokinetic (“

PBPK”

) model.

14. The device of claim 1 wherein the feature or the permeable material is integrated into a chip format.

15. The device of claim 1 wherein the permeable material comprises a layer of gastrointestinal enterocytes cultured on a microporous material.

16. The device of claim 15 wherein at least a portion of the layer of gastrointestinal enterocytes is positioned in the device such that fluid may flow along either side of but not through the layer.

17. The device of claim 16 wherein at least a first microscale feature located on a first side of the layer of gastrointestinal enterocytes represents the gastrointestinal tract and wherein at least a second microscale feature located on a second side of the monolayer represents a circulatory system.

18. The device of claim 17 further comprising a third microscale feature that is configured to contain the same or a different type of biological material.

19. The device of claim 1 wherein the permeable material comprises a microporous material coated at least in part with an organic material.

20. The device of claim 1 further comprising cells located in, on or near both sides of the permeable material.

21. The device of claim 20 wherein the device provides absorption characteristics, metabolic enzyme activity and/or expression levels.

22. The device of claim 20 wherein the cells on either side of the permeable material are of the same type or of different types.

23. The device of claim 1 further comprising hepatocytes in, on or near a microporous surface of the permeable material.

24. The device of claim 23 wherein at least a portion of the microporous surface comprises proteins that polarize the hepatocytes.

25. The device of claim 1 wherein the permeable material comprises a cell line capable of forming a confluent monolayer.

26. The device of claim 1 further comprising a binder that binds hepatocytes to the permeable material.

27. The device of claim 26 wherein the binder polarizes the hepatocytes.

28. The device of claim 26 wherein the binder comprises at least one selected from the group consisting of a protein, connexin 32, a tight junction protein, occludin, claudin-1, ZO-1, ZO-2, an adherens junction protein, E-cadherin, beta-catenin, a cell adhesion molecule, and uvomorulin.

29. The device of claim 1 further comprising a second type of biological material in, on or near the permeable material.

30. The device of claim 1 further comprises fibroblasts in, on or near the permeable material.

31. The device of claim 1 further comprising a blood surrogate flow in proximity to a first side of the permeable material.

32. The device of claim 31 further comprising a bile surrogate flow in proximity to a second side of the permeable material.

33. A method comprising:

maintaining biological material under conditions that provide a value of at least one pharmacokinetic parameter in vitro that is comparable to the value of at least one pharmacokinetic parameter found in vivo; and

passing a substance through at least a portion of a permeable material.

34. The method of claim 33 further comprising maintaining the biological material within or in proximity to a microscale feature.

35. The method of claim 33 wherein the permeable material is selected from at least one of the group consisting of a membrane, a porous membrane, microporous silicon, a semi-permeable membrane, a microporous material, a microporous polymer, alginate, collagen, MATRIGEL, cells, cellular material, tissue, and pieces of tissue.

36. The method of claim 33 wherein the permeable material further comprises organic or inorganic material in, on or near a microporous surface.

37. The method of claim 33 wherein the permeable material is configured to simulate at least one of a biological barrier, passage of substances in or through a biological barrier, or absorption of substances in, through or by a biological barrier.

38. The method of claim 37 wherein the biological barrier is selected from at least one of the group consisting of a gastrointestinal barrier, a blood-brain barrier, a blood-biliary barrier, a pulmonary barrier, a placental barrier, an epidermal barrier, ocular barrier, olfactory barrier, a gastroesophageal barrier, a mucous membrane, a blood-urinary barrier, and an air-tissue barrier, oral barrier, anal rectal barrier, vaginal barrier, and urethral barrier.

39. The method of claim 33 wherein the at least one pharmacokinetic parameter is selected from at least one of the group consisting of tissue size, tissue size ratio, tissue to blood volume ratio, drug residence time, interactions between cells, liquid residence time, liquid to cell ratios, metabolism by cells, shear stress, flow rate, geometry, circulatory transit time, liquid distribution, interactions between tissues and/or organs, and molecular transport by cells.

40. The method of claim 33 further comprising determining absorption, metabolism, or distribution of the substance in, through or by the permeable material.

41. The method of claim 34 wherein the feature is configured to represent at least one of the group consisting of at least portions of central nervous, circulatory, digestive, biliary, pulmonary, urinary, ocular, olfactory, epidermal, and lymphatic systems.

42. The method of claim 33 further comprising locating the permeable material in or external to a microscale device.

43. The method of claim 33 further comprising flowing fluid through at least one microfluidic channel connected to the permeable material.

44. The method of claim 33 wherein the flow of fluid in, through, or in proximity to the permeable material provides the at least one pharmacokinetic parameter.

45. The method of claim 44 wherein the characteristics of the fluid flow through the device are based on a mathematical model.

46. The method of claim 45 wherein the mathematical model is a physiologically-based pharmacokinetic (“

PBPK”

) model.

47. The method of claim 33 further comprising integrating the microscale feature or the permeable material into a chip format.

48. The method of claim 33 wherein the permeable material comprises a layer of gastrointestinal enterocytes cultured on a microporous material.

49. The method of claim 48 further comprising positioning at least a portion of the layer of gastrointestinal enterocytes such that fluid may flow along either side of but not through the layer.

50. The method of claim 49 wherein at least a first microscale feature located on a first side of the layer of gastrointestinal enterocytes represents the gastrointestinal tract and wherein at least a second microscale feature located on a second side of the monolayer represents a circulatory system.

51. The method of claim 50 further comprising a third microscale feature that is configured to contain the same or a different type of biological material.

52. The method of claim 33 wherein the permeable material comprises a microporous material coated at least in part with an organic material.

53. The method of claim 33 further comprising locating cells in, on or near both sides of the permeable material.

54. The method of claim 53 further comprising providing absorption characteristics, metabolic enzyme activity and/or expression levels.

55. The method of claim 53 wherein the cells on either side of the permeable material are of the same type or of different types.

56. The method of claim 33 further comprising locating hepatocytes in, on or near a microporous surface of the permeable material.

57. The method of claim 56 wherein at least a portion of the microporous surface comprises proteins that polarize the hepatocytes.

58. The method of claim 33 wherein the permeable material comprises a cell line capable of forming a confluent monolayer and polarizing.

59. The method of claim 33 further comprising binding hepatocytes to the permeable material.

60. The method of claim 59 further comprising polarizing the hepatocytes.

61. The method of claim 59 wherein the binding comprises a binder that is at least one selected from the group consisting of a protein, connexin 32, a tight junction protein, occludin, claudin-1, ZO-1, ZO-2, an adherens junction protein, E-cadherin, beta-catenin, a cell adhesion molecule, and uvomorulin.

62. The method of claim 33 further comprising locating a second type of biological material in, on or near the permeable material.

63. The method of claim 33 further comprising locating fibroblasts in, on or near the permeable material.

64. The method of claim 33 further comprising flowing a blood surrogate in proximity to a first side of the permeable material.

65. The method of claim 64 further comprising flowing a bile surrogate in proximity to a second side of the permeable material.

66. A method of forming a device comprising:

forming a feature that is configured to maintain biological material under conditions that provide a value of at least one pharmacokinetic parameter in vitro that is comparable to the value of at least one pharmacokinetic parameter found in vivo; and

adding, forming, or providing for a permeable material, wherein the permeable material is configured such that a substance passes through at least a portion of the permeable material.

67. A device comprising:

means for maintaining biological material under conditions that provide a value of at least one pharmacokinetic parameter in vitro that is comparable to the value of at least one pharmacokinetic parameter found in vivo; and

means for providing a permeable barrier.